Therapies for heart failure and related Cardiovascular Diseases. Sector: Healthcare. Country: Germany. Fund: LSP 5 Entry 2017. Axtarish: cardior.de

25 мар. 2024 г. · Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions ...

25 мар. 2024 г. · EQT Life Sciences portfolio company Cardior Pharmaceuticals has announced today that it will be acquired by Novo Nordisk for up to EUR 1.025 ...

25 мар. 2024 г. · The deal marks a significant exit for Cardior's largest shareholder EQT Life Sciences, whose predecessor LSP (Life Sciences Partners) led ...

Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company ...

25 мар. 2024 г. · Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen ...

EQT Life Sciences' portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk Monday, March 25th, 2024. Acquisition values Cardior ...

25 мар. 2024 г. · EQT Life Sciences' portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk. eqtgroup.com. 294 ...

On May 11, 2017, growth capital firm EQT Life Sciences invested in life science company Cardior.

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Ascenion's portfolio company Cardior Pharmaceuticals for up to EUR 1.025 billion including an upfront payment and additional ...